Biotechnology is hard enough all on its own without investors
complicating things with low-potential drugs in difficult markets. With
that in mind, I don't see significant opportunity in Omeros (OMER).
The company's near-term pipeline for ophthalmology and knee surgery
isn't all that promising, and the early-stage pipeline of MASP-2, PDE10,
PDE7, GPCR, and PPAR-gamma has far too little supporting data at this
point to validate a high valuation or multiple.
Please click the link for more:
Omeros Doesn't Look Like That Much Of An Opportunity
No comments:
Post a Comment